# US 2025/0223286 A1 · Immunomodulators, compositions and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0223286 A1
- Document ID: US20250223286A1
- Status: Published application
- Kind: A1
- Application number: 19/006,838
- Filed: 2024-12-31
- Published: 2025-07-10
- Earliest claimed: 2019-01-31
- Assignees: Betta Pharmaceuticals Co., Ltd.
- Applicants: Betta Pharmaceuticals Co.,Ltd
- Inventors: Yiqian WANG; Yao ZHANG; Bang FU; Jiabing WANG; Lieming DING
- Web page: https://patentgrep.com/patent/US20250223286A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D 471/04: Ortho-condensed systems
- C07D 471/08: Bridged systems
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 487/10: Spiro-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 495/10: Spiro-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

## Claims

### Claim 1

A compound of Formula (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof,
Wherein,
R1 and R2 are each independently selected from halogen, CN, C1-6alkyl, or C1-4 haloalkyl;
Q is a bond, —NH—, or —(CH2)m—O—;
Ring A is C5-6 aryl, C5-6 heteroaryl, C4-6cycloalkyl or C4-6heterocycloalkyl, wherein the C5-6 heteroaryl and C4-6heterocycloalkyl optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O; or
Ring A is C8-10 fused bicyclic ring;
R3 is H, halogen, —(CH2)s—NR4R5, C1-4 alkyl, C1-4 alkoxyl, hydroxyl, oxo, CN, (CH2)q—CONR4R5, —COR4, —NR4R5, —NR4C(═O)NR4R5, —NR4C(═NR4)NR4R5, —S(O)2R4, —S(O)2NR4R5, —S(O)R4, —S(O)NR4R5, C2-6 alkenyl, C2-6alknyl, C1-6haloalkyl, C5- 6 aryl, C5-6 heteroaryl, C3-6cycloalkyl or C3-6heterocycloalkyl, wherein the C5-6 heteroaryl and C3-6heterocycloalkyl optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O; the C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6alknyl, C1-6haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-6cycloalkyl and C3-6heterocycloalkyl optionally substituted with one or more substitutents independently selected R6 substituents;
R4 and R5 are each independently selected from H, C1-4 alkyl, or C3-6 cycloalkyl, C3-6 heterocyclyl, the C1-4 alkyl, C3-6 cycloalkyl, or C3-6 heterocyclyl optionally substituted with one or more substitutents independently selected R6 substituents; or
R4 and R5 together with the atoms to which they are attached form a 4-10-member heterocyclic ring optionally substituted with one or more substituents independently selected R6 substituents;
R6 is H, halogen, hydroxyl, oxo, CN, —(CH2)k—NR7R8, —COR7, —NR7R8, —NR7C(═O)NR7R8, —NR7C(═NR7)NR7R8, —S(O)2R7, —S(O)2NR7R8, —S(O)R7, —S(O)NR7R8, or R6 is selected from substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alknyl, C1-6haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-10 heterocyclic ring, wherein the C5-6 heteroaryl and C3-10 heterocyclic ring optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O;
R7 and R8 are each independently selected from H, halogen, hydroxyl, oxo, CN, —S(O)2—C1-4 alkyl, —NH2, —NH—C1-4 alkyl, —(CH2)—N(C1-4 alkyl)2, or R7 and R8 are each independently selected from substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6alknyl, C1-6haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-6cycloalkyl, C3-6heterocycloalkyl; wherein the C5-6 heteroaryl and C3-6heterocycloalkyl optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O;
m, n, q, k and s are each independently selected from 0, 1, 2, 3 or 4.

### Claim 2 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein,
R3 is H, halogen, —(CH2)s—NR4R5, C1-4 alkyl, C1-4 alkoxyl, hydroxyl, oxo, CN, (CH2)q—CONR4R5, —NR4R5, —NR4C(═NR4)NR4R5, —S(O)2R4, C2-6alkenyl, C2-6alknyl, C1-6haloalkyl or C3-6heterocycloalkyl, wherein the C3-6heterocycloalkyl optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O; the C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6alknyl, C1-6haloalkyl, and C3-6heterocycloalkyl optionally substituted with one or more substitutents independently selected R6 substituents.

### Claim 3 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein,
R3 is H, halogen, —(CH2)s—NR4R5, —CN, —S(O)2R4, C1-4 alkyl, C1-4 alkoxyl, the —(CH2)s—NR4R5, C1-4 alkyl, C1-4 alkoxyl optionally substituted with one or more substitutents independently selected R6 substituents.

### Claim 4 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein,
R6 is H, halogen, hydroxyl, oxo, CN, —(CH2)k—NR7R8, —COR7, —NR7R8, —NR7C(═O)NR7R8, —S(O)2R7 or R6 is selected from substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6alknyl, C1-6haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-10 heterocyclic ring, wherein the C5-6 heteroaryl and C3-10 heterocyclic ring optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O.

### Claim 5 (depends on 1)

The compound of any claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein,
R6 is H, halogen, hydroxyl, oxo, CN, —(CH2)—N—(C1-4 alkyl)2, —(CH2)—NH2, —N—(C1-4 alkyl)2, —NH2, —CO—N—(C1-4alkyl)2, —CO—NH2, —S(O)2—C1-4 alkyl, C1-4 alkyl-OH, C1-4 alkyl, C1-4 alkoxyl, C2-6alkenyl, C2-6alknyl, C1-6haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-10 heterocyclic ring, wherein the C5-6 heteroaryl and C3-10 heterocyclic ring optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O.

### Claim 6 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein,
R6 is halogen, oxo, —OH, —NH2, —N(CH3)2, —C1-4 alkyl-OH, —C1-4 alkyl-NH—CH3, —NH—C1-4 alkyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxyl, C5-6 aryl, C5-6 heteroaryl, C3-6 heterocyclyl, guanidine, or sulfone.

### Claim 7 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein,
R1 and R2 are each independently selected from halogen, CN, —C1-6alkyl, or —C1-4haloalkyl;
Q is a bond, —NH—, or —(CH2)m—O—;
ring A is C5-6 aryl or C5-6 heteroaryl ring, wherein the C5-6 heteroaryl ring optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O; or
ring A is C8-10 fused bicyclic ring;
R3 is H, halogen, —(CH2)s—NR4R5, —C1-4 alkyl, —C1-4 alkoxyl, the —(CH2)s—NR4R5, —C1-4 alkyl, —C1-4 alkoxyl optionally substituted with one or more substitutents independently selected from halogen, —C1-4 alkyl, —C1-4 haloalkyl, —C1-4 alkoxyl, C5-6 heteroaryl, C5-6 aryl, carboxyl, amino, hydroxyl, guanidine, or sulfone;
R4 and R5 are each independently selected from H, —C1-4 alkyl, or C3-6 cycloalkyl, C3-6 heterocyclyl, the —C1-4 alkyl, or C3-6 cycloalkyl, C3-6 heterocyclyl optionally substituted with halogen, —OH, N(CH3)2, —C1-4 alkyl, —C1-4haloalkyl, —C3-6 heterocyclyl, —NH—C1-4 alkyl, or sulfone; or
R4 and R5 together with the atoms to which they are attached form a 4- to 6-member heterocyclic ring optionally substituted with one or more substituents independently selected from —OH, —N(CH3)2, —NH2, oxo, halogen, —C1-4 alkyl, —C1-4 alkoxyl, —C1-4 alkyl-OH, —C1-4 alkyl-NH—CH3, or sulfone;
m, n and s are each independently selected from 0, 1, 2, 3 or 4.

### Claim 8 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein Q is selected from bond, —NH— or —CH2—O—.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound having Formula(III):
or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein, ring C is phenyl.

### Claim 10 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein R1 is selected from —CH3, F, or —O—CH3.

### Claim 11 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein R2 is —CH3.

### Claim 12 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein s is 1.

### Claim 13 (depends on 1)

The compound of claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof, wherein m is 1.

### Claim 14 (depends on 1)

A method of treating a disease associated with inhibition of PD-1/PD-L1 interaction, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disease is colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, pancreatic cancer, melanoma, multiple melanoma, brain cancer, renal cancer, prostate cancer, ovarian cancer or breast cancer.

### Claim 16 (depends on 1)

A method of enhancing, stimulating and/or increasing the immune response in a patient, said method comprising administering to the patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof.
